Advertisement

European Journal of Nutrition

, Volume 55, Issue 8, pp 2357–2364 | Cite as

The effects of coenzyme Q10 administration on glucose homeostasis parameters, lipid profiles, biomarkers of inflammation and oxidative stress in patients with metabolic syndrome

  • Fariba Raygan
  • Zohreh Rezavandi
  • Sahar Dadkhah Tehrani
  • Alireza Farrokhian
  • Zatollah AsemiEmail author
Original Contribution

Abstract

Background

Limited data are available indicating the effects of coenzyme Q10 (CoQ10) supplementation on metabolic status of patients with metabolic syndrome (MetS).

Purpose

The present study was conducted to determine the effects of CoQ10 administration on glucose homeostasis parameters, lipid profiles, biomarkers of inflammation and oxidative stress among patients with MetS.

Methods

This randomized, double-blind, placebo-controlled trial was performed among 60 overweight or obese and type 2 diabetes mellitus patients with coronary heart disease aged 40–85 years old. Participants were randomly allocated into two groups. Group A (n = 30) received 100 mg CoQ10 supplements and group B (n = 30) received placebo for 8 weeks. Fasting blood samples were taken at the beginning of the study and after 8-week intervention to quantify glucose homeostasis parameters, lipid profiles and biomarkers of inflammation and oxidative stress.

Results

Compared with the placebo, CoQ10 supplementation resulted in a significant reduction in serum insulin levels (−2.1 ± 7.1 vs. +4.1 ± 7.8 µIU/mL, P = 0.002) and homeostasis model of assessment-insulin resistance (−0.7 ± 2.1 vs. +1.0 ± 2.0, P = 0.002) and homeostatic model assessment-beta cell function (−5.9 ± 22.2 vs. +15.9 ± 34.0, P = 0.005). In addition, patients who received CoQ10 supplements had a significant increase in plasma total antioxidant capacity (TAC) concentrations (+26.0 ± 105.0 vs. −162.2 ± 361.8 mmol/L, P = 0.008) compared with the placebo group. However, after adjustment for the baseline levels, age and baseline BMI, the effect on TAC levels (P = 0.08) disappeared. Additionally, compared with the placebo group, a significant positive trends in plasma glutathione (P = 0.06) and a significant reduction in malondialdehyde (P = 0.08) were seen among patients who received CoQ10 supplement. We did not observe any significant changes in fasting plasma glucose, lipid concentrations and inflammatory markers.

Conclusions

Overall, daily intake of 100 mg CoQ10 supplements among patients with MetS for 8 weeks had beneficial effects on serum insulin levels, HOMA-IR, HOMA-B and plasma TAC concentrations.

Clinical trial registration number

www.irct.ir: IRCT201502245623N35.

Keywords

Coenzyme Q10 Supplementation Metabolic syndrome Type 2 diabetes mellitus Coronary heart disease 

Notes

Acknowledgments

The current study was founded by a grant from the Vice-chancellor for Research, KUMS, Iran. The authors would like to thank the staff of Naghavi Clinic (Kashan, Iran) for their assistance in this project.

Authors’ contributions

Z.A. contributed in conception, design, statistical analysis and drafting of the manuscript. F.R., Z.R., S.D. and A.F. contributed in data collection and manuscript drafting. All authors approved the final version for submission. Z.A. supervised the study. All authors approved the final version for submission.

Compliance with ethical standards

Conflict of interest

None of the authors had any personal or financial conflict of interest.

References

  1. 1.
    Miles MV, Morrison JA, Horn PS, Tang PH, Pesce AJ (2004) Coenzyme Q10 changes are associated with metabolic syndrome. Clin Chim Acta 344(1–2):173–179CrossRefGoogle Scholar
  2. 2.
    Chokrungvaranon N, Deer J, Reaven PD (2011) Intensive glycemic control and cardiovascular disease: are there patients who may benefit? Postgrad Med 123(6):114–123CrossRefGoogle Scholar
  3. 3.
    Sivitz WI, Yorek MA (2010) Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. Antioxid Redox Signal 12(4):537–577CrossRefGoogle Scholar
  4. 4.
    Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54(6):1615–1625CrossRefGoogle Scholar
  5. 5.
    Fiorentino TV, Prioletta A, Zuo P, Folli F (2013) Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases. Curr Pharm Des 19(32):5695–5703CrossRefGoogle Scholar
  6. 6.
    Suksomboon N, Poolsup N, Juanak N (2015) Effects of coenzyme Q supplementation on metabolic profile in diabetes: a systematic review and meta-analysis. J Clin Pharm Ther 40(4):413–418CrossRefGoogle Scholar
  7. 7.
    Garrido-Maraver J, Cordero MD, Oropesa-Avila M, Fernandez Vega A, de la Mata M, Delgado Pavon A, de Miguel M, Perez Calero C, Villanueva Paz M, Cotán D, Sánchez-Alcázar JA (2014) Coenzyme q10 therapy. Mol Syndromol 5(3–4):187–197Google Scholar
  8. 8.
    Miyake Y, Shouzu A, Nishikawa M, Yonemoto T, Shimizu H, Omoto S, Hayakawa T, Inada M (1999) Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients. Arzneimittelforschung 49(4):324–329Google Scholar
  9. 9.
    Hodgson JM, Watts GF, Playford DA, Burke V, Croft KD (2002) Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr 56(11):1137–1142CrossRefGoogle Scholar
  10. 10.
    Lee BJ, Huang YC, Chen SJ, Lin PT (2012) Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with coronary artery disease. Nutrition 28(3):250–255CrossRefGoogle Scholar
  11. 11.
    Lee BJ, Huang YC, Chen SJ, Lin PT (2012) Effects of coenzyme Q10 supplementation on inflammatory markers (high-sensitivity C-reactive protein, interleukin-6, and homocysteine) in patients with coronary artery disease. Nutrition 28(7–8):767–772CrossRefGoogle Scholar
  12. 12.
    Lee YJ, Cho WJ, Kim JK, Lee DC (2011) Effects of coenzyme Q10 on arterial stiffness, metabolic parameters, and fatigue in obese subjects: a double-blind randomized controlled study. J Med Food 14(4):386–390CrossRefGoogle Scholar
  13. 13.
    Amin MM, Asaad GF, Abdel Salam RM, El-Abhar HS, Arbid MS (2014) Novel CoQ10 antidiabetic mechanisms underlie its positive effect: modulation of insulin and adiponectine receptors, tyrosine kinase, PI3K, glucose transporters, sRAGE and visfatin in insulin resistant/diabetic rats. PLoS ONE 9(2):e89169CrossRefGoogle Scholar
  14. 14.
    Carmona MC, Lefebvre P, Lefebvre B, Galinier A, Benani A, Jeanson Y, Louche K, Flajollet S, Ktorza A, Dacquet C, Pénicaud L, Casteilla L (2009) Coadministration of coenzyme Q prevents rosiglitazone-induced adipogenesis in ob/ob mice. Int J Obes (Lond) 33(2):204–211CrossRefGoogle Scholar
  15. 15.
    Schmelzer C, Lindner I, Rimbach G, Niklowitz P, Menke T, Doring F (2008) Functions of coenzyme Q10 in inflammation and gene expression. BioFactors 32(1–4):179–183CrossRefGoogle Scholar
  16. 16.
    Farhangi MA, Alipour B, Jafarvand E, Khoshbaten M (2014) Oral coenzyme Q10 supplementation in patients with nonalcoholic fatty liver disease: effects on serum vaspin, chemerin, pentraxin 3, insulin resistance and oxidative stress. Arch Med Res 45(7):589–595CrossRefGoogle Scholar
  17. 17.
    Welles CC, Whooley MA, Karumanchi SA, Hod T, Thadhani R, Berg AH, Ix JH, Mukamal KJ (2014) Vitamin D deficiency and cardiovascular events in patients with coronary heart disease: data from the Heart and Soul Study. Am J Epidemiol 179(11):1279–1287CrossRefGoogle Scholar
  18. 18.
    Pisprasert V, Ingram KH, Lopez-Davila MF, Munoz AJ, Garvey WT (2013) Limitations in the use of indices using glucose and insulin levels to predict insulin sensitivity: impact of race and gender and superiority of the indices derived from oral glucose tolerance test in African Americans. Diabetes Care 36(4):845–853CrossRefGoogle Scholar
  19. 19.
    Tatsch E, Bochi GV, Pereira Rda S, Kober H, Agertt VA, de Campos MM, Gomes P, Duarte MM, Moresco RN (2011) A simple and inexpensive automated technique for measurement of serum nitrite/nitrate. Clin Biochem 44(4):348–350CrossRefGoogle Scholar
  20. 20.
    Benzie IF, Strain JJ (1996) The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. Anal Biochem 239(1):70–76CrossRefGoogle Scholar
  21. 21.
    Beutler E, Gelbart T (1985) Plasma glutathione in health and in patients with malignant disease. J Lab Clin Med 105(5):581–584Google Scholar
  22. 22.
    Janero DR (1990) Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med 9(6):515–540CrossRefGoogle Scholar
  23. 23.
    Asemi Z, Khorrami-Rad A, Alizadeh SA, Shakeri H, Esmaillzadeh A (2014) Effects of synbiotic food consumption on metabolic status of diabetic patients: a double-blind randomized cross-over controlled clinical trial. Clin Nutr 33(2):198–203CrossRefGoogle Scholar
  24. 24.
    Park E (2010) Birth weight was negatively correlated with plasma ghrelin, insulin resistance, and coenzyme Q10 levels in overweight children. Nutr Res Pract 4(4):311–316CrossRefGoogle Scholar
  25. 25.
    Mehmetoglu I, Yerlikaya FH, Kurban S (2011) Correlation between vitamin A, E, coenzyme Q(10) and degree of insulin resistance in obese and non-obese subjects. J Clin Biochem Nutr 49(3):159–163CrossRefGoogle Scholar
  26. 26.
    Kolahdouz Mohammadi R, Hosseinzadeh-Attar MJ, Eshraghian MR, Nakhjavani M, Khorami E, Esteghamati A (2013) The effect of coenzyme Q10 supplementation on metabolic status of type 2 diabetic patients. Minerva Gastroenterol Dietol 59(2):231–236Google Scholar
  27. 27.
    Gokbel H, Gergerlioglu HS, Okudan N, Gul I, Buyukbas S, Belviranli M (2010) Effects of coenzyme Q10 supplementation on plasma adiponectin, interleukin-6, and tumor necrosis factor-alpha levels in men. J Med Food 13(1):216–218CrossRefGoogle Scholar
  28. 28.
    Lee BJ, Tseng YF, Yen CH, Lin PT (2013) Effects of coenzyme Q10 supplementation (300 mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: a randomized, placebo-controlled trial. Nutr J 12(1):142. doi: 10.1186/1475-2891-12-142 CrossRefGoogle Scholar
  29. 29.
    Diaz-Castro J, Guisado R, Kajarabille N, Garcia C, Guisado IM, de Teresa C, Ochoa JJ (2012) Coenzyme Q(10) supplementation ameliorates inflammatory signaling and oxidative stress associated with strenuous exercise. Eur J Nutr 51(7):791–799CrossRefGoogle Scholar
  30. 30.
    Mancini A, Milardi D, Bianchi A, Festa R, Silvestrini A, De Marinis L, Pontecorvi A, Meucci E (2007) Increased total antioxidant capacity in seminal plasma of varicocele patients: a multivariate analysis. Arch Androl 53(1):37–42CrossRefGoogle Scholar
  31. 31.
    Watts GF, Playford DA, Croft KD, Ward NC, Mori TA, Burke V (2002) Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. Diabetologia 45(3):420–426CrossRefGoogle Scholar
  32. 32.
    Crane FL (2001) Biochemical functions of coenzyme Q10. J Am Coll Nutr 20(6):591–598CrossRefGoogle Scholar
  33. 33.
    Arroyo A, Kagan VE, Tyurin VA, Burgess JR, de Cabo R, Navas P, Villalba JM (2000) NADH and NADPH-dependent reduction of coenzyme Q at the plasma membrane. Antioxid Redox Signal 2(2):251–262CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Fariba Raygan
    • 1
  • Zohreh Rezavandi
    • 1
  • Sahar Dadkhah Tehrani
    • 2
  • Alireza Farrokhian
    • 1
  • Zatollah Asemi
    • 2
    Email author
  1. 1.Department of Cardiology, School of MedicineKashan University of Medical SciencesKashanIran
  2. 2.Research Center for Biochemistry and Nutrition in Metabolic DiseasesKashan University of Medical SciencesKashanIran

Personalised recommendations